Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Rangaswamy Govindarajan

Concepts (139)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Colonic Neoplasms
3
2016
162
0.710
Why?
Anus Neoplasms
1
2018
26
0.550
Why?
Antineoplastic Combined Chemotherapy Protocols
3
2020
1043
0.480
Why?
Embolism
1
2015
18
0.470
Why?
Bone Marrow Neoplasms
1
2015
13
0.460
Why?
Gene Regulatory Networks
1
2016
112
0.450
Why?
Carcinoma, Squamous Cell
1
2018
332
0.450
Why?
Tumor Lysis Syndrome
1
2014
6
0.430
Why?
Leukemia, Lymphocytic, Chronic, B-Cell
1
2014
59
0.420
Why?
Neoplasm Recurrence, Local
1
2018
647
0.420
Why?
Pyrazoles
1
2014
123
0.400
Why?
Pyrimidines
1
2014
206
0.390
Why?
Angiogenesis Inhibitors
2
2006
186
0.390
Why?
Clinical Trials as Topic
5
2019
466
0.380
Why?
Salvage Therapy
1
2013
138
0.370
Why?
Actinomycosis
1
2012
10
0.370
Why?
Biliary Tract Diseases
1
2012
14
0.370
Why?
Bile Duct Neoplasms
1
2012
29
0.370
Why?
Stomach Neoplasms
1
2015
207
0.360
Why?
Middle Aged
13
2024
13422
0.340
Why?
Prognosis
6
2019
2118
0.340
Why?
Gene Expression Profiling
1
2016
1112
0.340
Why?
Benzenesulfonates
2
2011
10
0.330
Why?
Carcinoma, Hepatocellular
1
2013
213
0.320
Why?
Stroke
1
2015
520
0.320
Why?
Pyridines
2
2011
135
0.300
Why?
Liver Neoplasms
1
2013
347
0.300
Why?
Colorectal Neoplasms
2
2003
302
0.280
Why?
Aged, 80 and over
6
2018
3495
0.260
Why?
Heparin
1
2007
86
0.250
Why?
Drug Industry
1
2007
39
0.250
Why?
Thrombocytopenia
1
2007
89
0.250
Why?
Hypertensive Encephalopathy
1
2006
3
0.250
Why?
raf Kinases
1
2006
4
0.250
Why?
Communication Barriers
1
2007
35
0.250
Why?
Aged
10
2024
10430
0.250
Why?
Thiazolidinediones
1
2007
81
0.250
Why?
Isoantigens
1
2026
15
0.240
Why?
Oncolytic Virotherapy
1
2026
28
0.230
Why?
Carcinoma, Pancreatic Ductal
1
2026
43
0.230
Why?
Female
13
2026
28792
0.230
Why?
Adult
10
2024
14541
0.220
Why?
Thrombosis
1
2007
250
0.220
Why?
Skin
1
2007
420
0.210
Why?
Anticoagulants
1
2007
280
0.210
Why?
Humans
18
2026
53246
0.210
Why?
CTLA-4 Antigen
1
2024
32
0.210
Why?
Enzyme Inhibitors
1
2006
371
0.210
Why?
Immunotherapy
1
2026
266
0.200
Why?
Tumor Microenvironment
1
2026
274
0.200
Why?
Pancreatic Neoplasms
1
2026
219
0.200
Why?
Prostatic Neoplasms
1
2007
401
0.200
Why?
Survival Rate
2
2018
949
0.200
Why?
Male
11
2024
27444
0.190
Why?
Follow-Up Studies
3
2019
2318
0.190
Why?
Camptothecin
1
2002
14
0.180
Why?
Antineoplastic Agents, Phytogenic
1
2002
71
0.170
Why?
Lung Neoplasms
1
2007
645
0.160
Why?
Oximes
1
2020
17
0.160
Why?
Pyrimidinones
1
2020
19
0.160
Why?
Diabetes Mellitus, Type 2
1
2007
591
0.160
Why?
Pyridones
1
2020
38
0.160
Why?
Thalidomide
1
2002
378
0.150
Why?
Imidazoles
1
2020
114
0.150
Why?
Cholangiocarcinoma
2
2011
27
0.150
Why?
Protein Kinase Inhibitors
1
2020
234
0.140
Why?
Survival Analysis
3
2020
659
0.130
Why?
Antineoplastic Agents
2
2019
1232
0.130
Why?
Melanoma
1
2020
277
0.130
Why?
Combined Modality Therapy
1
2018
640
0.120
Why?
Neoplasm Staging
2
2013
774
0.120
Why?
Severity of Illness Index
1
2019
1049
0.120
Why?
Antibodies, Monoclonal
1
2019
477
0.110
Why?
Skin Neoplasms
1
2020
500
0.110
Why?
Gene Amplification
1
2015
58
0.110
Why?
Adenine
1
2014
29
0.110
Why?
Genes, myc
1
2015
39
0.110
Why?
Polycomb Repressive Complex 2
1
2015
48
0.110
Why?
Retrospective Studies
3
2018
6821
0.110
Why?
United States
3
2019
5413
0.100
Why?
Piperidines
1
2014
99
0.100
Why?
Gene Deletion
1
2015
279
0.100
Why?
Treatment Outcome
4
2020
5597
0.100
Why?
Registries
3
2007
652
0.100
Why?
Quinazolines
1
2013
34
0.100
Why?
Leukemia, Myeloid, Acute
1
2015
208
0.090
Why?
Actinomyces
1
2012
12
0.090
Why?
Gene Expression Regulation, Neoplastic
1
2016
868
0.090
Why?
Endoscopy, Gastrointestinal
1
2012
73
0.090
Why?
Comorbidity
2
2019
638
0.090
Why?
Gallbladder Neoplasms
1
2011
7
0.090
Why?
Antibodies, Monoclonal, Humanized
1
2013
238
0.090
Why?
Phenylurea Compounds
2
2011
18
0.080
Why?
Niacinamide
2
2011
24
0.080
Why?
Incidence
2
2019
1085
0.080
Why?
Neoplasms
1
2019
1335
0.070
Why?
Necrosis
1
2007
169
0.060
Why?
Drugs, Investigational
1
2007
14
0.060
Why?
Causality
1
2007
53
0.060
Why?
Tomography, X-Ray Computed
1
2012
1183
0.060
Why?
Hospitals, University
1
2007
75
0.060
Why?
Neoplasm Metastasis
2
2011
237
0.060
Why?
Confidence Intervals
1
2007
158
0.060
Why?
Age Distribution
1
2007
175
0.060
Why?
Probability
1
2007
171
0.060
Why?
United States Food and Drug Administration
1
2007
93
0.060
Why?
Anti-Bacterial Agents
1
2012
832
0.060
Why?
Medical Oncology
1
2007
97
0.060
Why?
Syndrome
1
2006
248
0.060
Why?
Patient Selection
1
2007
273
0.060
Why?
Publication Bias
1
2005
14
0.050
Why?
Editorial Policies
1
2005
14
0.050
Why?
Programmed Cell Death 1 Receptor
1
2024
46
0.050
Why?
Adolescent
2
2024
6912
0.050
Why?
Periodicals as Topic
1
2005
63
0.050
Why?
Dose-Response Relationship, Drug
1
2007
1367
0.050
Why?
Young Adult
2
2024
4514
0.050
Why?
Risk Assessment
1
2007
1368
0.050
Why?
Cell Line, Tumor
1
2026
1470
0.040
Why?
MAP Kinase Kinase Kinases
1
2020
19
0.040
Why?
Socioeconomic Factors
1
2003
623
0.040
Why?
Proto-Oncogene Proteins B-raf
1
2020
78
0.040
Why?
Mutation, Missense
1
2020
110
0.040
Why?
Drug Administration Schedule
1
2020
370
0.040
Why?
Trisaccharides
1
2019
1
0.040
Why?
Premedication
1
2019
17
0.040
Why?
Magnetic Resonance Imaging
1
2006
1587
0.040
Why?
Administration, Oral
1
2020
456
0.040
Why?
Antibodies
1
2019
147
0.040
Why?
Infusions, Intravenous
1
2019
211
0.040
Why?
Prospective Studies
1
2024
2412
0.040
Why?
Health Services Accessibility
1
2003
477
0.030
Why?
Disease Management
1
2019
187
0.030
Why?
Arkansas
1
2003
2068
0.030
Why?
Mice
1
2026
5982
0.030
Why?
In Situ Hybridization, Fluorescence
1
2015
266
0.030
Why?
Polymorphism, Single Nucleotide
1
2015
505
0.020
Why?
Animals
1
2026
13528
0.020
Why?
Disease-Free Survival
1
2011
466
0.020
Why?
Govindarajan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description